Early clinical experience with subcutaneous GR43175 in acute migraine: an overview

P Tfelt-Hansen, J Brand, P Dano, A Doenicke, L J Findley, Helle Klingenberg Iversen, D Melchart, H M Sahlender

Research output: Contribution to journalJournal articleResearchpeer-review

27 Citations (Scopus)

Abstract

In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume9 Suppl 9
Pages (from-to)73-7
Number of pages5
ISSN0333-1024
Publication statusPublished - 1989

Keywords

  • Adolescent
  • Adult
  • Aged
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Indoles
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Migraine Disorders
  • Sulfonamides
  • Sumatriptan

Cite this